PAD Profile : Tapentadol hydrochloride - Pain (non-malignant)

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Tapentadol hydrochloride - Pain (non-malignant)

PAD Profile : Tapentadol hydrochloride - Pain (non-malignant) Important

Keywords :

Opioid analgesia, opioid analgesics

Brand Names Include :

Palexia, Palexia SR, Ationdo SR, Tapimio, Vacicom

Important Information :

Only on recommendation by a pain specialist for patients not responding to / not tolerating morphine or oxycodone

Traffic Light Status

Status 1 of 1.

Status :

Blue

Formulations :

Modified release tablets
Tablets

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Meptazinol hydrochloride

Other Indications

No indications returned.

Additional Documents

Type

Document

Review Date

Information

Tapentadol - MHRA drug safety update - January 2019.pdf

Committee Recommendations

Date

Committee Name

Narrative

05 June 2019

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The APC supports the use of tapentadol SR as a treatment option for the management of severe persistent non-malignant pain in adults after assessment and recommendation by a pain specialist for patients not responding to / not tolerating morphine OR oxycodone.

Due to the similar mode of action and relative efficacy of tapentadol compared with tramadol, it would be appropriate to have tried tramadol before initiating tapentadol.

Tapentadol SR will be considered as BLUE (no information sheet) on the traffic light system.

Please be aware of the MHRA drug safety update (January 2019- attached below) in relation to potential increase in seizure risk in patients taking other medicines

Associated BNF Codes

04. Central Nervous System

04.07.02. Opioid analgesics